INCY
HEALTHCAREIncyte Corp
$99.85+2.38 (+2.44%)LIVE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving INCY Today?
No stock-specific AI insight has been generated for INCY yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$58.94$112.29
$99.85
Fundamentals
Market Cap$19.9B
P/E Ratio14.1
EPS$7.08
Dividend Yield—
Dividend / Share—
ROE0.3%
Profit Margin0.3%
Debt / Equity—
Trading
Volume1.2M
Avg Volume (10D)—
Shares Outstanding199.8M
INCY News
24 articles- Incyte Corp. Receives Favorable Valuation Adjustment Amid Strong Financial PerformanceMarkets Mojo·May 9, 2026
- Does Jakafi XR Approval And Pipeline Progress Change The Bull Case For Incyte (INCY)?Yahoo Finance·May 8, 2026
- Mirum's Q1 Earnings & Revenues Beat Estimates, 2026 View RaisedYahoo Finance·May 7, 2026
- Incyte presents 24-week data for ruxolitinib cream in atopic dermatitisInvesting.com·May 7, 2026
- Incyte eczema cream held disease control through 24 weeksStock Titan·May 7, 2026
- Incyte Announces 24-Week Long-Term Data from Phase 3 TRuE-AD4 Trial of Opzelura® (ruxolitinib) Cream in Adults with Moderate Atopic DermatitisYahoo Finance·May 7, 2026
- Xencor (NASDAQ: XNCR) posts deeper Q1 2026 loss amid royalty dispute and Zenas write-downStock Titan·May 7, 2026
- Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Yahoo Finance·May 6, 2026
- MacroGenics and Sagard Healthcare Partners Enter into Expanded ZYNYZ® Royalty Purchase AgreementYahoo Finance·May 4, 2026
- Incyte (INCY) Positioned to Offset Patent Cliff Risks, Analysts Reaffirm Stock RatingsYahoo Finance·May 2, 2026
- Incyte Announces FDA Approval of Jakafi XR™ (ruxolitinib) Extended-Release Tablets for the Treatment of Myelofibrosis, Polycythemia Vera and Graft-Versus-Host DiseaseYahoo Finance·May 1, 2026
- Earnings Beat: Incyte Corporation Just Beat Analyst Forecasts, And Analysts Have Been Updating Their ModelsYahoo Finance·May 1, 2026
- Incyte to Present at Upcoming Investor ConferencesYahoo Finance·Apr 29, 2026
- Company News for Apr 29, 2026Yahoo Finance·Apr 29, 2026
- Incyte Corp (INCY) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and Promising ...Yahoo Finance·Apr 29, 2026
- Incyte Wavers As Growth Questions Plague Its Up-And-Coming DrugYahoo Finance·Apr 28, 2026
- Incyte (INCY) Q1 2026 Earnings Call TranscriptMotley Fool·Apr 28, 2026
- Incyte (INCY) Q2 2025 Earnings TranscriptMotley Fool·Apr 28, 2026
- Incyte Corporation Q1 2026 Earnings Call SummaryMoby·Apr 28, 2026
- INCY Q1 Earnings and Revenues Beat Estimates on Higher Product SalesYahoo Finance·Apr 28, 2026
- Incyte Q1 Earnings Call HighlightsMarketbeat·Apr 28, 2026
- Compared to Estimates, Incyte (INCY) Q1 Earnings: A Look at Key MetricsYahoo Finance·Apr 28, 2026
- Incyte (INCY) Beats Q1 Earnings and Revenue EstimatesYahoo Finance·Apr 28, 2026
- Incyte (NASDAQ:INCY) Exceeds Q1 CY2026 ExpectationsYahoo Finance·Apr 28, 2026
All 24 articles loaded
Price Data
Open$98.62
Previous Close$97.47
Day High$100.01
Day Low$97.61
52 Week High$112.29
52 Week Low$58.94
52-Week Range
$58.94$112.29
$99.85
Fundamentals
Market Cap$19.9B
P/E Ratio14.1
EPS$7.08
Dividend Yield—
Dividend / Share—
ROE0.3%
Profit Margin0.3%
Debt / Equity—
Trading
Volume1.2M
Avg Volume (10D)—
Shares Outstanding199.8M
About Incyte Corp
Incyte Corp is an American pharmaceutical company based in Alapocas, Delaware.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—